Clinical Trials
9 trialsNCT01251861 2026-05-29
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01200810 2017-12-02
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT00486642 2017-05-24
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00108732 2015-06-30
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666666 2014-12-18
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00348998 2013-11-06
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003517 2013-07-10
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn